by emil.fuerst@lvl-up.ch | Oct 17, 2022 | General
The RDAF co-signed a joint statement with other stakeholders on the revision of the Health Insurance Ordinance (KVV/OAMal) and Health Benefits Ordinance (KLV/OPAS). The statement highlights the potential negative impacts of the revision, including the following:... by emil.fuerst@lvl-up.ch | Oct 3, 2022 | General
In line with this concern, the RDAF would like to draw attention to the fact that the planned revision of the Health Insurance Ordinance (KVV), contrary to its stated objective, threatens patients’ access to treatment. Read our media release here. by soxedoze | Sep 16, 2022 | General
The Rare Disease Action Forum has published a position paper in relation to the consultation organized by the Federal Office of Public Health on the revision of the Health Insurance Ordinance (KVV/OAMal) and the Health Benefits Ordinance (KLV/OPAS). In its position... by soxedoze | Jun 29, 2022 | General
The newsletter, which is published twice a year, gives an overview of all the Rare Disease Action Forum (RDAF) activities during the past half year to raise awareness about rare diseases in Switzerland and improve patient’s access to diagnosis, treatment and care.... by soxedoze | Jan 10, 2022 | General, Members
We are proud to welcome UCB Pharma and HOPOS as the newest members of the Rare Disease Action Forum. Reinforcing RDAF’s multi-stakeholder approach, they will be joining our other members including industry, patient organizations, healthcare professionals, and research... by soxedoze | Jul 14, 2021 | Events, General, Publications
The Rare Disease Action Forum (RDAF) published the report about its multi-stakeholder workshop on ‘Registries for rare diseases in Switzerland’ which took place on 30 June 2021. The report provides an overview of the expert presentations and summarizes the exchanges...